


PHARMACEUTICAL 2020

UroGen Pharma Ltd. Rank 196 of 362











UroGen Pharma Ltd. Rank 196 of 362

The relative strengths and weaknesses of UroGen Pharma Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UroGen Pharma Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 105% points. The greatest weakness of UroGen Pharma Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is -203%, being 100% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	148,634
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,482
Liabilities, Non-Current	2,604
Other Assets	52,777
Other Compr. Net Income	276
Other Expenses	0
Other Liabilities	0
Other Net Income	4,332
Property and Equipment	977
Research and Development	49,297
Revenues	18
Selling, General and Administrative Expense	60,199

Output Variable	Value in 1000 USD
Assets	202,388
Liabilities	22,086
Expenses	109,496
Stockholders Equity	180,302
Net Income	-105,146
Comprehensive Net Income	-105,008
Economic Capital Ratio	-203%

